OBX-115 Elicits Responses in Advanced or Metastatic Melanoma
Source: OncLive, December 2023
The tumor-infiltrating lymphocyte (TIL) cell therapy OBX-115 produced responses with no dose-limiting toxicities (DLTs) in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor (ICI) therapy, according to topline data from a phase 1 trial (NCT05470283).
At a median follow-up of 18 weeks, and a data cutoff date of December 1, 2023, OBX-115 induced an objective response rate (ORR) of 50% by investigator assessment and RECIST v1.1 criteria; this included 2 complete responses and 1 partial response. The disease control rate (DCR) was 100%.
Data from the study also support the validation of the cytoDRiVE technology for the regulation of membrane-bound IL-15 to allow controlled proliferation, strengthened persistence and antitumor activity of adoptive T-cell agents.